L’Oréal relaxers and cancer: an agreement in the United States revives concerns

L'Oréal relaxers and cancer: an agreement in the United States revives concerns
In the United States, L’Oréal USA and several hair product manufacturers reached a confidential settlement with four women who sued them, believing that hair straightening products contributed to their cancer. This news raises questions about the potential risks of these products, while a study published in 2022 had already highlighted an association between their frequent use and an increased risk of uterine cancer.

The information was reported on November 16, 2026 by Reuters. The four women had initiated legal proceedings in Chicago, United States, claiming that the use of straightening and straightening products caused gynecological cancers.

These are the first cases in this dispute to have advanced to the trial phase. But be careful with interpretation: this agreement does not constitute an acknowledgment of liability by L’Oréal nor scientific proof that a particular product causes cancer.

Relaxers: why is L’Oréal affected by a legal settlement in the United States?

The agreement reached between L’Oréal USA, other manufacturers and the four plaintiffs puts an end to their civil proceedings. Its amount has not been made public.

However, this legal outcome does not mean that a court has established a causal link between the use of relaxers and the appearance of cancer. An amicable agreement allows a dispute to be resolved without necessarily deciding the alleged responsibilities.

According to Reuters, L’Oréal USA said it remains confident in the safety of its SoftSheen-Carson products. The group also recalls that the available scientific data does not demonstrate a causal link.

We must therefore distinguish two subjects: on the one hand, the accusations made in the context of legal proceedings and, on the other, scientific knowledge concerning the possible effects of certain hair products on health.

On this second point, a study published in 2022 provides elements that deserve attention.

A 2022 study observed an association between relaxers and uterine cancer

In October 2022, researchers published in the Journal of the National Cancer Institute the results of a study devoted to the use of hair products and the risk of uterine cancer.

Their work was based on data from the Sister Study, a prospective cohort that followed 33,947 American women aged 35 to 74 and with a uterus at the start of the study.

Over an average period of 10.9 years, 378 participants developed uterine cancer.

Researchers have notably observed an association between the use of hair straightening, straightening or pressing products and a higher rate of uterine cancer.

The signal was particularly strong among frequent users, defined in this study as women who reported more than four uses during the twelve months preceding their inclusion.

The estimates presented by the National Institutes of Health (NIH) give an order of magnitude: approximately 1.64% of women who had never used these products and 4.05% of frequent users were estimated to be likely to develop uterine cancer before age 70.

Be careful, however: these results show a statistical association, not a cause and effect relationship. They therefore do not allow us to assert that relaxers are directly responsible for the cancers observed.

What ingredients could be involved?

One of the main limitations of this study concerns precisely the products used by the participants.

The researchers did not collect the names of the brands or the exact composition of the formulas applied. It is therefore impossible to identify, from this work, a particular brand or ingredient as responsible for the observed association.

Several families of substances are nevertheless mentioned as avenues to explore, in particular certain compounds likely to interfere with the hormonal system or presenting a carcinogenic potential: parabens, bisphenol A, metals or even formaldehyde.

These hypotheses do not allow us to conclude that all of these substances were present in the products used by the participants, nor that they alone explain the results.

Another interesting element: the researchers did not find the same association with the other hair products studied, in particular dyes, bleaches, highlights or perms.

It would therefore be excessive to generalize these results to all hairdressing products and practices.

Relaxers: should you stop using them?

These results call for vigilance, particularly among women who use hair straightening products very regularly. However, they do not justify concluding that a person who has already used these products will develop cancer.

In the absence of evidence to identify a responsible formula or ingredient, it remains difficult to precisely quantify the individual risk associated with each product.

If there is any concern, it is possible to question the frequency of use and limit avoidable exposures. The composition of the products also deserves special attention.

It is also important not to confuse the different smoothing techniques. Chemical relaxers, certain straighteners and products containing glyoxylic acid do not necessarily correspond to the same formulations or the same health risks. The results of the American study cannot therefore be extrapolated to all hair care products marketed in France.

What gynecological symptoms should alert you?

Beyond questions about hair products, certain gynecological symptoms should lead to seeking medical advice.

Health Insurance reminds in particular that vaginal bleeding after menopause should always be the subject of a consultation, even when it is not very abundant or only occurs once. Before menopause, unusual bleeding, particularly between periods, or abnormally heavy or irregular periods, also warrant medical advice. These manifestations do not necessarily mean that cancer is present. They nevertheless require research into their origin. Depending on the situation, the assessment may include a clinical examination, a pelvic ultrasound and, if necessary, an endometrial biopsy.

The main thing is therefore not to draw hasty conclusions based on past use of a hair product, but also not to trivialize unusual gynecological symptoms.